

Resignation of Non-executive Director

SYDNEY, AUSTRALIA – 4 October 2024 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces independent non-executive director (NED), Anne Anderson, has tendered her resignation effective from 4 October 2024. Accordingly, she will not seek election as a Director of the Company by shareholders at the Company’s upcoming Annual General Meeting.

Dr Russell Howard, Chairman of Immutep, said “Anne has been a valued member of the Board since her appointment in February 2024, contributing to the strength of our risk management and governance. On behalf of the Board, I would like to thank her for her contribution to the success of Immutep and wish her every success with her next endeavours.”

The Board will review its requirements to support the Company’s next phase of growth. As an emerging global biotech with an extensive late-stage clinical program, the role of NED for Immutep currently demands sector knowledge.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:

Catherine Strong, Sodali & Co.

+61 (0)406 759 268; catherine.strong@sodali.com

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; chris.basta@immunept.com

This announcement was authorised for release by the Board of Immutep Limited.